Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 215-222

  Luo, Zhu Lin ^a,b   Tang, Li Jun ^a   Wang, Tao ^a   Dai, Rui Wu ^a   Ren, Jian Dong ^a   Cheng, Long ^a   Xiang, Ke ^a   Tian, Fu Zhou ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hydrogen sulfide; Inflammation; Methionine choline deficient diet; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINE; CYTOCHROME P450 2E1; FATTY ACID; HEME OXYGENASE 1; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METHIONINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; FATTY ACID METABOLISM; LIPID LIVER LEVEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

HYDROGEN SULFIDE; INFLAMMATION; METHIONINE-CHOLINE DEFICIENT DIET; NON-ALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS;

ANIMALS; CHOLINE DEFICIENCY; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HEME OXYGENASE-1; HYDROGEN SULFIDE; INFLAMMATION; INTERLEUKIN-6; LIVER; MALE; METHIONINE; MITOCHONDRIA, LIVER; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897589965     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12389     Document Type: Article

References (43)

1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009; 8 (Suppl. 1): S4-8.
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
3. Norris EJ, Culberson CR, Narasimhan S, Clemens MG. The liver as a central regulator of hydrogen sulfide. Shock 2011; 36: 242-250.
4. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol. Rev. 2012; 92: 791-896.
5. 2S production in murine tissues. Antioxid. Redox Signal. 2011; 15: 363-372.
6. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid. Redox Signal. 2010; 12: 1-13.
7. Rivers JR, Badiei A, Bhatia M. Hydrogen sulfide as a therapeutic target for inflammation. Expert Opin. Ther. Targets 2012; 16: 439-449.
8. Kang K, Zhao M, Jiang H, Tan G, Pan S, Sun X. Role of hydrogen sulfide in hepatic ischemia reperfusion-induced injury in rats. Liver Transpl. 2009; 15: 1306-1314.
9. Morsy MA, Ibrahim SA, Abdelwahab SA, Zedan MZ, Elbitar HI. Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice. Life Sci. 2010; 87: 692-698.
10. Hosono-Fukao T, Hosono T, Seki T, Ariga T. Diallyl trisulfide protects rats from carbon tetrachloride-induced liver injury. J. Nutr. 2009; 139: 2252-2256.
11. Tan G, Pan S, Li J etal. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PLoS ONE 2011; 6: e25943.
12. Serviddio G, Bellanti F, Tamborra R etal. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur. J. Clin. Invest. 2008; 38: 245-252.
13. Geng B, Cui Y, Zhao J etal. Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 293: R1608-1618.
14. Zhang L, Yang G, Untereiner A, Ju Y, Wu L, Wang R. Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes. Endocrinology 2013; 154: 114-126.
15. Yan Y, Chen C, Zhou H etal. Endogenous hydrogen sulfide formation mediates the liver damage in endotoxemic rats. Res. Vet. Sci. 2013; 94: 590-595.
16. 2S be the third endogenous gaseous transmitter? FASEB J. 2002; 16: 1792-1798.
17. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012; 52: 59-69.
18. Farombi EO, Surh YJ. Heme-oxygenase-1 as a potential therapeutic target for hepatoprotection. J. Biochem. Mol. Biol. 2006; 39: 479-491.
19. Wang RQ, Nan YM, Wu WJ etal. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis. 2011; 10: 31.
20. Nan Y, Wang R, Zhao S etal. Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. Lipids Health Dis. 2010; 9: 124.
21. Maher J. The CYP2E1 knockout delivers another punch: first ASH, now NASH. Alcoholic steatohepatitis. Nonalcoholic steatohepatitis. Hepatology 2001; 33: 311-312.
22. Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J. Hepatol. 2012; 57: 860-866.
23. Pérez-Carreras M, Del Hoyo P, Martín MA etal. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
24. Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J. Biol. Chem. 2007; 282: 21327-21336.
25. Senateş E, Colak Y, Yeşil A etal. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med. 2012; 103: 369-376.
26. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert. Rev. Gastroenterol. Hepatol. 2011; 5: 189-200.
27. Yamaguchi K, Itoh Y, Yokomizo C etal. Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice. Lab. Invest. 2011; 91: 609-618.
28. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. (Maywood) 2007; 232: 614-621.
29. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 1991; 10: 2247-2258.
30. Sanlioglu S, Williams CM, Samavati L etal. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J. Biol. Chem. 2001; 276: 30188-30198.
31. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins-regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur. J. Cell Biol. 2012; 91: 496-505.
32. Inoue M, Ohtake T, Motomura W etal. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem. Biophys. Res. Commun. 2005; 336: 215-222.
33. Takeuchi O, Sato S, Horiuchi T etal. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 2002; 169: 10-14.
34. Hoebe K, Georgel P, Rutschmann S etal. CD36 is a sensor of diacylglycerides. Nature 2005; 433: 523-527.
35. Semenkovich CF. Regulation of fatty acid synthase (FAS). Prog. Lipid Res. 1997; 36: 43-53.
36. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002; 109: 1125-1131.
37. Aoyama T, Peters JM, Iritani N etal. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998; 273: 5678-5684.
38. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-132.
39. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296.
40. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr. 2011; 141: 603-610.
41. Martin GG, Atshaves BP, McIntosh AL etal. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol. Cell. Biochem. 2009; 324: 101-115.
42. Martin GG, Atshaves BP, Huang H etal. Hepatic phenotype of liver fatty acid binding protein gene-ablated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 297: G1053-1065.
43. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.